Delcath Systems (NASDAQ:DCTH – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Insider & Institutional Ownership
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Delcath Systems and Pulse Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | 0.62% | 0.51% | 0.46% |
| Pulse Biosciences | N/A | -86.67% | -73.61% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $85.23 million | 5.27 | $2.70 million | $0.01 | 1,301.00 |
| Pulse Biosciences | $751,000.00 | 2,422.81 | -$72.78 million | ($1.10) | -23.90 |
Delcath Systems has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Delcath Systems and Pulse Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 1 | 1 | 5 | 0 | 2.57 |
| Pulse Biosciences | 1 | 0 | 3 | 0 | 2.50 |
Delcath Systems currently has a consensus target price of $22.50, indicating a potential upside of 72.94%. Pulse Biosciences has a consensus target price of $30.67, indicating a potential upside of 16.65%. Given Delcath Systems’ stronger consensus rating and higher probable upside, equities analysts clearly believe Delcath Systems is more favorable than Pulse Biosciences.
Risk & Volatility
Delcath Systems has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
Summary
Delcath Systems beats Pulse Biosciences on 10 of the 14 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
